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Foreword
People with intellectual disability use more medication than others in the population. 
They have a greater prevalence of physical and mental health disorders, for which they 
use medication. The issue on the overuse of psychotropic medication in people with 
intellectual disability was raised by parents in the Serious Case Review into Winterbourne 
View Hospital in 2012. People were using medications without there being clear clinical 
indications for needing them. The ensuing debate on people with intellectual disability 
and people with autism using psychotropic medication, has been salutary and has 
helped improve clinical practice. For psychiatrists and prescribers, the challenge is to 
use medication judiciously in order to avoid the unnecessary and inappropriate use of 
such potent drugs. The Royal College of Psychiatrists supports the STOMP pledge. 
Psychotropic medication is indicated as part of a treatment plan for mental disorder 
and not to manage behavioural difficulties that require a psychological approach.
The members of the Faculty of Psychiatry of Intellectual Disability have responded 
to the challenge, advocating clear prescribing practices and seeking alternatives to 
medication, with the support of family carers and multi-disciplinary clinical teams. Quality 
improvement initiatives are active in clinical services, supported by the growth of good 
evidence showing how prescribers support people to use medication optimally and 
how to choose alternative interventions.
The position statement is a very welcome addition to our clinical practice, that benefits 
from the inclusion of the insights of family carers and non-medical prescribers in the use 
of psychotropic medication. It expresses the approach that the Faculty of Psychiatry 
of Intellectual Disability encourages clinicians to pursue in prescribing as part of a 
clear care plan to support people. I thank all the contributors for their valuable work in 
this document and I commend it to all prescribers supporting people with intellectual 
disability.
Dr Ken Courtenay, Chair 
Faculty of Psychiatry of Intellectual Disability 
Royal College of Psychiatrists, UK
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This position statement was compiled by the cross-faculty working group for STOMP 
and STAMP and consulted patients with intellectual disability and/or autism and their 
carers. The working group was formed by the following:
Lead author and editor: 
Dr Asit B Biswas, Vice-Chair, Faculty of Psychiatry of Intellectual Disability, Royal 
College of Psychiatrists 
Working group members:
Professor David Baldwin, Chair, Psychopharmacology Committee
Dr Ken Courtenay, Chair, Faculty of Psychiatry of Intellectual Disability
Dr Avinash Hiremath, Medical Director, Leicestershire Partnership NHS Trust UK 
Dr Sujeet Jaydeokar, Faculty of Psychiatry of Intellectual Disability
Dr Mark Lovell, Faculty of Child and Adolescent Psychiatry and Faculty of Psychiatry 
of Intellectual Disability
Dr Heather McAlister, Faculty of Psychiatry of Intellectual Disability 
Dr Rohit Shankar, Faculty of Psychiatry of Intellectual Disability
In the process of drawing up the position statement, the group consulted the following 
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speech and language therapists, education and social care professionals, deprivation 
of liberty safeguards assessors, patient advocates and carers.
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Introduction
Stopping the overmedication of people with intellectual disability (ID), autism or 
both (STOMP) is a project supported by NHS England and is aimed at reducing the 
inappropriate prescribing of psychotropic medication to manage behaviour that is 
deemed to be challenging, in the absence of a documented mental health diagnosis 
(Branford et al, 2018; NHS England, 2016). The project was launched in 2016 following 
on from the report into the Winterbourne View Hospital which highlighted concerns 
related to the use of medication in this way (Department of Health, 2012); in particular 
the ‘off label’ and poorly evidenced use of psychotropic medication. Historically, limited 
guidance has been available to guide the appropriate use of psychotropic medication 
in managing challenging behaviour in people with ID (Tyrer et al, 2008; Deb et al, 2007, 
2009). Transforming Care (2012) and the concordat identified the issue. Three reports 
were commissioned – one using general practice data (Glover et al, 2015), a best practice 
guide Psychotropic drug prescribing for people with intellectual disability, mental health 
problems and/or behaviours that challenge: practice guidelines (RCPsych, 2016) and 
a survey of medication for detained patients with intellectual disability (Care Quality 
Commission, 2016), provided the evidence and need for the STOMP programme.
Concerns about the extent and potential overuse of psychotropic medication, particularly, 
but not exclusively, antipsychotics and antidepressants in people with intellectual disability, 
have been reported for many years. The Serious Case Review into Winterbourne View 
Hospital highlighted the inappropriate use of medication and subsequent reports 
identified the need to take action. As a result, Public Health England estimated that up 
to 35,000 adults with intellectual disability are using psychotropic medicines when they 
do not have health conditions which are regarded as indications for medication. (PHE, 
2015). There is clear evidence that a disproportionate number of people with intellectual 
disability in community settings are prescribed antipsychotics and antidepressants. Public 
Health England reported that 17% of people known to have intellectual disability were 
prescribed antipsychotics and 16.9% were using antidepressants. (Glover et al, 2015).
NHS England launched the STOMP programme in 2015, to reduce the extent of 
overprescribing and inappropriate prescribing, in people with intellectual disability.
STOMP stands for stopping overmedication of people with intellectual disability, autism 
or both, with psychotropic medication and is a national project in England involving 
different organisations. Psychotropic medication is defined as any medication capable 
of affecting the mind, emotions and behaviour. STOMP aims to help people to stay well 
and have a good quality of life.
The programme drew upon a Public Health England study documenting the extent of 
prescribing of psychotropic medication by general practitioners (GPs). STOMP-STAMP 
was launched in December 2018 by NHS England and The Royal College of Paediatrics 
and Child Health (RCPCH). The RCPCH, the British Association of Childhood Disability 
(BACD) and the Council for Disabled Children (CDC) pledged to ensure that children 
and young people with intellectual disability, autism or both, have access to appropriate 
medication [in line with National Institute for Health and Care Excellence (NICE) guidance] 
but are not prescribed inappropriate medication. Further, they affirmed that regular and 
timely reviews should be undertaken so that the effectiveness of medication is evaluated 
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and balanced against potential side effects. This should ensure that children and young 
people only use the right medication, at the right time, for the right reason.
The organisations pledged to work together with children and young people with 
intellectual disability, autism or both and their parents, carers and families, to take 
measurable steps to ensure that children and young people only receive medication 
that effectively improves their lives; to set out the actions that individual organisations will 
take towards this shared aim; and to report regularly on the progress made, ensuring 
accountability.
This position statement outlines the Royal College of Psychiatrist’s position on STOMP 
and STAMP.
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What does STOMP aim to achieve?
All healthcare providers who prescribe psychotropic medication to people with intellectual 
disability, autism or both, are asked to adopt and achieve the STOMP healthcare pledge:
• We will actively explore alternatives to medication
• We will ensure people with intellectual disability, autism or both, of any age, and 
their circle of support, are fully informed about their medication and involved in 
decisions about their care
• We will ensure all staff within the organisation have an understanding of psychotropic 
medication, including why it is being used and its potential side effects
• We will ensure all people are able to speak up if they have a concern that someone 
is receiving inappropriate medication
• We will maintain accurate records about a person’s health, well-being and behaviour
• We will ensure that medication, if needed, is started, reviewed and monitored in 
line with relevant NICE guidance
• We will work in partnership with people with intellectual disability, autism or both, 
their families, care teams, healthcare professionals, commissioners and others to 
stop overmedication.
The position statement supports the pledge on behalf of the Royal College of Psychiatrists 
(RCPsych).
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The role of the psychiatrist in STOMP-STAMP
Any psychiatrist/nurse prescriber and any clinician with a licence to prescribe psychotropic 
medications should do so appropriately, keeping in mind the principles of medical ethics, 
including beneficence, non-maleficence, autonomy and justice. The effective use of 
psychotropic medication needs to be for the right indication, for the right reason and 
with appropriate monitoring for side effects, in order to improve the quality of life of the 
individuals in their care.
Individuals in community settings referred to intellectual disability services may present 
with behaviours that challenge or that pose increased risks to both themselves and 
others. There is a need to reduce the risks and an apparent solution may be to utilise 
medication in the short term as part of a multi-disciplinary approach. In many cases, 
this leads to using antipsychotics, benzodiazepines or other medications that sedate or 
calm, in order to achieve a rapid reduction in behaviours that challenge. However, this 
may be followed by their long-term use. Moreover, treatment-emergent behavioural side 
effects with psychotropic medication, such as selective serotonin reuptake inhibitors, 
have been reported in people with intellectual disabilities (Biswas AB et al, 2001). Hence, 
there needs to be clear evidence to suggest that the use of medication is effective in 
reducing risk and improving a person’s quality of life and not, in themselves, causing 
or escalating behavioural problems.
Glover et al (2014) raised doubts about the effectiveness of medication in these 
circumstances. They provide evidence that the use of antipsychotic medication in the 
long term is inappropriate in the management of behaviour that challenges. It further 
suggests that in cases where there is no underlying mental illness, medication is often 
used to treat ‘the symptom, not the cause’. Additionally, in some cases a reduction 
in medication is associated with an improvement in presentation. There is therefore 
evidence to suggest that the use of such psychotropic medication may not effectively 
deal with the underlying problems or significantly improve quality of life.
It is of note that a recent systematic review of the available evidence on the reduction 
or discontinuation of antipsychotics in adults with intellectual disability using it because 
of challenging behaviour, concluded that, although the relevant evidence was limited 
in scope and quality, withdrawal of medication led to behavioural deterioration for 
some people, with no evident personal characteristics distinguishing the group who 
experienced adverse side effects (Sheehan and Hassiotis, 2017).
Nonetheless, the long-term administration of psychotropic medications can be associated 
with significant side effects and physical health problems. Such problems may include 
extrapyramidal side effects such as tremor, dyskinesia, muscular rigidity and tardive 
dyskinesia.
Moreover, these medications can be associated with obesity, risk of developing metabolic 
syndrome, severe cardiovascular problems, haematological problems and an increase in 
the risk of developing diabetes (De Hert et al, 2011). This requires special consideration 
as there is evidence that people with intellectual disability have poorer health than their 
non-disabled peers (Emerson and Baines, 2010).
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Any clinician prescribing psychotropic medication should ascertain the evidence of its 
efficacy and appropriateness for the person. Prescribers should therefore weigh up the 
possible positive effects of a reduction in risk, anxiety and distress with the possible 
negative effects of side effects and other physical health concerns.
Glover et al (2014) explored the reasons for prescribing medication. Psychiatrists/clinicians 
are asked to intervene in intense and high-risk situations, typically to avoid hospital 
admission or placement breakdown. Psychotropic medication prescribed to manage 
an acute crisis situation must be reviewed regularly to avoid routine continuation.
There are now well-developed behavioural techniques, e.g. applied behaviour analysis 
(LaVigna and Willis, 2005) and frameworks, such as positive behavioural support (Gore 
et al, 2013), that can improve the lives of those with intellectual disability who display 
challenging behaviours. NICE guidelines advise on the management of people with 
behaviour that challenges (NICE guidelines, 2015).
The guidelines emphasise the need to consider medication only when psychological 
intervention is ineffective or the immediate risk is very severe. Psychotropic medication 
should be offered in combination with psychological and other interventions. Any 
medication initiated should be monitored regularly and stopped if not associated with 
a clear improvement in quality of life.
The clinical consultation and medication review
Considering all of the above, the clinician/prescriber needs to gain a thorough 
understanding of the potential benefits and adverse effects of the medication on each 
individual in their care. There should be rigorous scrutiny of the need for medication, 
the effects of non-psychopharmacological therapies and a clear clinical objective to 
utilise the minimum dosage of medication, if medication is indicated.
It is recommended that the following points should be considered by care providers 
and families when preparing for the clinical consultation and review of medication for 
the child or adult with intellectual disability:
1 All psychiatric consultations/reviews should be person-centred and care providers, 
family, social workers, teachers, respite carers may be required to support individuals 
with intellectual disability, in order to ensure a clinically effective interview.
2 The person (with mild intellectual disability) may be able to provide necessary 
information. Nonetheless, it would be important and useful for an identified key 
worker with the knowledge and information on medication to support the service 
user to attend the consultation.
3 The psychiatrist should ensure that the person’s family and care providers and 
others involved in the care and support of the person with intellectual disability are 
aware of, and invited to, the appointment and are involved in the process from the 
outset, unless this is against the wishes of the service user.
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4 They should ensure that the support worker accompanying the service user knows 
them well, preferably for many years. This will enable the support worker to report 
changes in the service user’s presentation to the psychiatrist. The support worker 
should also have experience of working in the service user’s home and be aware 
of changes in personal or social circumstances that may affect the person. The 
support worker should have knowledge of additional physical health problems 
(for example constipation or urinary tract infection) which may affect the person.
5 Relevant details of medication, such as the current Medication Administration Record 
Sheet (MARS), with clear timings of medication changes must be brought to the 
appointment. This should include the frequency and reasons for the administration 
of any ‘as required’ or PRN medication. Details of other treatments/changes in 
medication by the GP or hospital clinic for physical health and changes in care 
plans should be brought to the appointment. Discharge summaries from acute 
hospital admissions should be available.
6 The care provider should supply the relevant recording of behavioural records and 
other information, such as sleep charts, for examination at the psychiatric review.
7 A core part of the psychiatric review is an in-depth review of the psychiatric diagnosis 
and rationale for use of psychotropic medication, weighing up benefits against 
potential or actual risks and focusing on the impact on the individual’s presentation 
and quality of life.
8 The aim should be to achieve the maximum benefit with the most optimum/
minimum dosage of psychotropic medication for the targeted action and to plan 
a timescale for stopping the medication where possible.
9 The clinical consultation and medication review should put in context the effects 
and role of behavioural interventions and other therapies in order to gain a holistic 
picture of the person’s well-being.
10 The outcome of the review will be fed back to the service user’s GP to ensure a 
unified approach and understanding of the person’s presentation and needs.
11 Input from the GP should be clarified and agreed in the context of local shared 
care arrangements, including, for example, monitoring for metabolic syndrome and 
potential adverse effects such as parkinsonian, cardiovascular and haematological 
side effects.
12 It is important to clarify that annual health checks at the GP surgery or by a 
paediatrician (for children at school) are arranged and completed. They typically 
include measurement of height, weight, body mass index, blood pressure, pulse, 
blood tests including tests of liver and kidney function, glycated haemoglobin 
and serum lipid profile and an electrocardiogram. Other tests such as a full blood 
count and thyroid function tests may be necessary depending on the psychotropic 
medication being prescribed.
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Social care providers
The STOMP partner, VODG (Voluntary Organisations Disability Group), was commissioned 
to produce a social care pledge that has been signed by more than 150 providers. 
Between them, they support more than 50,000 people with intellectual disability, autism 
or both.
VODG has produced useful resources, such as a booklet about supporting people 
when they visit the doctor, that includes an easy read section for the person. Social care 
providers can sign up to the STOMP pledge at the Voluntary Organisations Disability 
Group (VODG) website.
VODG has produced a booklet to help support workers accompany the people they 
support to a GP appointment to ask about psychotropic medication. The booklet 
includes an easy read section for the supporter.
The role of the general practitioner and primary care in STOMP-STAMP
Stopping overmedication of people with an intellectual disability (STOMP) has been 
co-produced by the Royal Colleges of Nursing, Psychiatrists and GPs, as well as the 
Royal Pharmaceutical Society, the British Psychological Society and NHS England. 
The Royal College of General Practitioners has updated and published its health 
checks for people with learning disabilities toolkit https://www.rcgp.org.uk/clini-
cal-and-research/resources/toolkits/health-check-toolkit.aspx which includes advice 
on medication reviews and the need to reduce psychotropic medication in adults 
with intellectual disability.
GPs may have a different role for children and adolescents, with medication being 
initiated and overseen by paediatricians and/or child psychiatrists.
The role of pharmacy services
Public Health England Intellectual Disability Observatory published a guide for staff in 
pharmacy and intellectual disability support teams in 2017 on best practice in supporting 
people with intellectual disability, autism or both.
The Centre for Pharmacy Postgraduate Education has launched online learning for 
pharmacists to develop awareness, understanding and key skills to help them deliver 
high-quality care.
Other health professionals
The Royal College of Nursing’s guidance for pre-registration education students 
(across all branches) on intellectual disability includes a section on overmedication. 
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Patients and carers
You can be a STOMP-STAMP supporter whether you are a person with intellectual 
disability, autism or both, a family carer, voluntary organisation, health or social care 
professional:
• Ask your healthcare (psychiatrist, GP, nurse) and social care providers (social worker) 
if they have signed up to STOMP and what they are doing to stop overmedication 
with psychotropic drugs.
• Give them the web address england.nhs.uk/stomp or https://www.england.nhs.
uk/publication/stomp-stamp-pledge-resources/ for all the information they need 
to get started.
• Share the easy read leaflet about STOMP
• Tell family carers about the resources on the Challenging Behaviour Foundation.
• Download the Royal College of Paediatrics and Child Health document https://
www.england.nhs.uk/wp-content/uploads/2019/06/stomp-stamp-family-leaflet.pdf 
• Use social media to tell others what you are doing about STOMP. The Twitter 
hashtag is #WeSupportSTOMP.
• If you are a professional, find out what your professional body’s STOMP commitments 
are on their website.
• Another useful resource is the Medication Pathway, published by the challenging 
behaviour foundation for family carers with someone with intellectual disability, 
autism or both, who are looking for information and guidance about psychotropic 
medication https://medication.challengingbehaviour.org.uk/pathway/
The role of advocates
The role of advocates and advocacy groups are vitally important. Advocacy groups such 
as VoiceAbility aim to ensure that people are supported to have control over their lives.
Advocacy provides an important function in ensuring people’s views about their 
medication are heard, that their rights are upheld and they are supported to make their 
own choices and enjoy a good life. To find out more about how advocates can help, 
STOMP Top Tips for Advocates has been written by and for advocates and includes 
ten ways to help stop the overmedication of people with intellectual disability, autism 
or both.
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In summary
STOMP has formalised the need to ensure that children or adults with intellectual 
disability use psychotropic medication appropriately. Clinicians in primary and secondary 
care services should prioritise plans to reduce psychotropic medication in a safe and 
closely monitored way.
In certain clinical situations, medication is beneficial and necessary. Prescribers should 
have clear evidence to demonstrate this and medication should routinely be utilised in 
conjunction with other therapies. Regular review of medication for its effectiveness is 
essential.
With the development of positive behavioural support, clinical care should focus its 
primary management on behaviour that challenges. STOMP-STAMP has prioritised 
this process in line with NICE guidance.
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Recommendations for action
1 Effective multidisciplinary working with joined up care plans and care pathways
a Psychiatrists have a key leadership role in assessing and overseeing the 
comprehensive assessment and treatment of a person with intellectual disability, 
autism or both, presenting with ‘behaviours that challenge’. This oversight is 
typically in partnership with a behavioural specialist, psychologist, speech and 
language therapist, occupational therapist, physiotherapist, GP, other physicians, 
outreach or community nursing, education and allied professionals, depending 
on the needs of the person.
b Detailed assessment and formulation is required by all involved clinicians, multi-
disciplinary and multi-agency teams. Some service provider organisations have 
board-certified behavioural analysts, dedicated positive behavioural support 
(PBS) or applied behaviour analysis (ABA) practitioners who lead on behavioural 
functional assessment, liaising with local clinicians.
2 Psychotropic medication prescribing for the right indication, for the right reason, 
at the right time
a Should the person need to use psychotropic medication, it should be by a 
prescriber “...who is competent in the care of people with intellectual disability” 
and in line with “Psychotropic drug prescribing for people with intellectual 
disability, mental health problems and/or behaviours that challenge: practice 
guidelines” (Faculty of Psychiatry of Intellectual Disability, 2016).
b For a diagnosis of a mental disorder, the treatment should follow relevant NICE 
guidelines and appropriate treatment for that clinical condition. If no mental 
disorder is present, then the prescription of psychotropic medication should be 
avoided, except for short-term use in which there is a serious risk of harm to the 
person and/or others, while other non-pharmacological plans are developed 
and implemented. In such instances, a drive to reduce and stop psychotropic 
medication must be a key focus after the crisis has resolved.
c The issue of behaviour that challenges, as a result of lockdown measures in the 
COVID-19 pandemic, may be difficult for carers to manage using the person’s 
current positive behavioural support plan and plans should be revised during the 
pandemic. This may lead to a greater reliance on medication to support a person to 
remain in their current residence (Courtenay K and Perera B, 2020) that is contrary 
to initiatives to reduce the use of psychotropic medication among people with ID 
(Branford et al, 2019). The use of psychotropic medication, prescribed on an ‘as 
required’ basis is often misunderstood by support teams as it is difficult to determine 
when it is appropriate to offer this. This can lead to both overuse or underuse unless 
there are clear PRN protocols established and available whereby medication is only 
used as a last resort after all available and practicable behavioural interventions 
have been exhausted. As with regularly prescribed psychotropic medication, there 
should be a commitment to stop ‘as required’ psychotropic medication for people 
who are not prescribed this to alleviate mental health symptoms.
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3 Mental capacity legislation and best interest decisions
a It is essential that psychiatrists/clinicians genuinely engage with and listen to the 
person with intellectual disability, their families/advocates and service providers, 
with regard to the short-term use of psychotropic medication for mental illness 
and/or behaviours that challenge.
b In children with intellectual disability, appropriate legal frameworks should be 
adhered to including the Children Act, parental responsibility, mental capacity 
and mental health legislation.
c Easy read patient and drug information leaflets should be provided and reasonable 
adjustments made to meet a person’s needs regarding their understanding.
d Compliance with the mental capacity legislation is essential. Where best interest 
decisions involving all stakeholders are important in the care of the individual 
concerned, there needs to be a clear plan/pathway leading to reduction and 
stopping the use of psychotropic medication for behaviours that challenge.
4 Effective monitoring psychotropic medication
a All prescriptions for psychotropic medication must be reviewed and evaluated 
regularly in line with NICE guidance, quality standards and good practice 
guidance.
b Adherence to STOMP and STOMP-STAMP psychotropic drug prescribing 
practice guidelines (Faculty of Psychiatry of Intellectual Disability, 2016) is also 
needed.
c Health service providers should have digital information technology systems in 
place to ensure regular clinical/medication reviews take place and alerts sent 
out if they are not.
d Monitoring systems should be in place for auditing the effectiveness of medication 
reviews and follow through both in primary and secondary care for quality 
improvement.
e Psychiatrists/prescribers are urged to use structured tools when monitoring 
the effectiveness of psychotropic medicines. A list of some of the instruments 
in use are listed below.
 − LUNSERS (Liverpool University Neuroleptic Side Effect Rating Scale) – used 
to record side effects (Day et al, www.reach4resource.co.uk/node/104).
 − CGI (Clinical Global Impression Scale) – this is freely available online and 
can be administered quickly by a clinician who knows the person well.
 − HoNOS-LD (Health of the Nation Outcome Scale-LD) and HoNOSCA 
(Health of the Nation Outcome Scale for children and adolescents) – 
monitors change over time (Royal College of Psychiatrists, 2016).
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 − Self-help reporting: this may be possible in some people who can be 
supported and provide frequent opportunities to report on changes 
they are experiencing with a psychotropic medication and a reduction/
discontinuation plan. This can be arranged through accessible self-reporting 
processes, frequent interviews with the person by their family carer or 
team leader/manager/keyworker at the care home or using a specific tool.
 − A guided self-help diary such as the SAINT (Self-Assessment and 
INTervention, Chaplin et al, 2014) and structured tools for children, may 
be helpful to support the person to focus on day-to-day moods/thoughts 
and feelings and provide an ongoing means of monitoring these and how 
the person responds/copes with day-to-day events/stressors.
5 Review of positive behaviour support (PBS) plans
a Positive behaviour support is defined as “A multi-component framework 
for developing an understanding of behaviour that challenges” (Gore et al, 
2013). PBS is now recommended as best practice by the Royal College of 
Psychiatrists, The Royal College of Speech and Language Therapists and The 
British Psychological Society. It is recommended by the Department of Health, 
NHS England and Skills for Care, and by the All Wales Challenging Behaviour 
Community of Practice.
b Essentially, the goals of PBS are to enhance a person’s quality of life and 
reduce behaviour that may be considered challenging. A PBS approach involves 
producing a comprehensive and detailed assessment of a person’s individualised 
needs, skills and behaviours, and designing strategies, reviewing and adjusting 
support styles and environments to increase competence and quality of life 
of the individual; thereby reducing behaviours that challenge. Collaboration 
and a shared understanding are essential parts of a PBS process. Successful 
implementation depends on the PBS professional working in partnership with 
the person, families, staff and other stakeholders in gathering information and 
designing strategies.
c PBS is likely to include training for people supporting an individual and focuses 
on leadership to develop staff understanding and working practices. Whilst PBS 
may appear to be costly, research shows that overall PBS, including training, 
costs less and has greater positive outcomes than other models of behaviour 
management (Hassiotis et al, 2009; Hunter et al, 2020).
6 Lifestyle changes and harm minimisation advice
a Advice and signposting on living a healthy lifestyle, a balanced diet and regular 
exercise in order to proactively anticipate and manage potential side effects 
including weight gain due to psychotropic medication.
b Addressing smoking, alcohol and other substance abuse.
7 To establish effective partnership between healthcare commissioners and providers, 
social care, patients, carers and clinicians, using NICE guidance.
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NICE guideline [NG 93] should be followed in keeping with reducing restrictive practices. 
This guideline covers services for children, young people and adults with intellectual 
disability (or autism and intellectual disability) and behaviours that challenge. It aims 
to promote a lifelong approach to supporting people and their families and carers by 
focusing on prevention and early intervention, and minimising inpatient admissions.
We Support STOMP network
This is a network set up particularly for people who lead on STOMP work from all walks 
of life. Here you can discuss implementation of STOMP and access or share files, videos 
and announcements. 
Transforming Care – STOMP online learning
Anyone working in a Transforming Care Partnership (TCP) or who is delivering care 
and support to people with intellectual disability, autism or both, can find a Medicines 
Management module designed for them within the Transforming Intellectual Disability 
Services online course (or MOOC – massive open online course). The link takes you to 
a sign-in page where new users should enrol for an account. Course 3 on Medicines 
Management is based on a series of short films by pharmacists, people with intellectual 
disability, a family carer and a specialist in positive behavioural support. The course 
links to useful PDFs and other websites for further information.
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Resources 
Resources listed below used in the preparation of this position statement are duly 
acknowledged.
• STOMP-STAMP leaflet: empowering those caring for children and young people 
with intellectual disability, autism or both, to ask questions and be more involved 
in discussions on their care.
• STOMP-STAMP principles: Explanation of the principles and reasons to pledge.
• STOMP-STAMP pledge: The pledge which can be signed by people on behalf of 
organisations.
• STOMP-STAMP leaflet: Provides more information on what STOMP-STAMP is.
• STOMP-STAMP Member of Parliament (MP) pledge: Write to your local MP to ask 
to make changes with regards to STOMP-STAMP in your region.
• STOMP-STAMP blank “I pledge to”: Write your pledge, take a photo and tweet.
• Positive Behavioural Support (PBS)
• NHS: Supporting Treatment and Appropriate Medication in Paediatrics (STAMP)
• NHS England and NHS Improvement: STOMP-STAMP launch event video: 
Owen and Sarah Thomas
• NICE: Learning disabilities and behaviour that challenges overview
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Appendix 
Other resources
• Healthcare providers wishing to support the pledge should contact 
england.wesupport.stomp@nhs.net by email.
• The healthcare provider will be sent an information pack to help develop their action 
plan and self-assessment which should be emailed back to the email address 
once completed.
• The STOMP professional resources page also links to individual STOMP resources 
for GPs, psychiatrists, psychologists, pharmacists, nurses and others.
• STOMP-STAMP pledge can be signed at  
www.england.nhs.uk/wp-content/uploads/2019/02/STOMP-STAMP-pledge.pdf 
alongside other resources.
